Substance / Medication

Desvenlafaxine

Overview

Active Ingredient

desvenlafaxine

RxNorm CUI

734064

Indications

[see Clinical Studies (14)] Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD).

Labeler: Sun Pharmaceutical Industries, Inc.Updated: 2023-08-07T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

[see Warnings and Precautions (5.1)]. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over a

Contraindications

When this intervention should not be used

[see Adverse Reactions (6.1)] Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. Angioedema has been reported in patients treated with desvenlafaxine. [see Dosage and Administration (2.7) Warnings

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Major depressive disorder

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Katzman Martin A, Nierenberg Andrew A, Wajsbrot Dalia B et al. · J Clin Psychopharmacol · 2017

PMID: 28817491Meta-AnalysisFull text (PMC)

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

Mosca Daniel, Zhang Min, Prieto Rita et al. · J Clin Psychopharmacol · 2017

PMID: 28146000Meta-Analysis

An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

Carrasco José L, Kornstein Susan G, McIntyre Roger S et al. · Int Clin Psychopharmacol · 2016

PMID: 26895080Meta-Analysis

Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis.

Laoutidis Z G, Kioulos K T · Pharmacopsychiatry · 2015

PMID: 26205685Meta-Analysis

Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.

Berhan Yifru, Berhan Asres · Ethiop J Health Sci · 2014

PMID: 25183927Meta-AnalysisFull text (PMC)

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.

Soares Claudio N, Fayyad Rana S, Guico-Pabia Christine J · J Clin Psychopharmacol · 2014

PMID: 24346751Meta-Analysis

Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.

Sun Zheng, Hao Yanqing, Zhang Min · Gynecol Obstet Invest · 2013

PMID: 23548358Meta-Analysis

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy Sujana, Kane Cecelia, Pitrosky Bruno et al. · Curr Med Res Opin · 2010

PMID: 19919295Meta-Analysis

Analysis of reward behavior in patients with MDD and partial response to SSRI therapy treated with vortioxetine versus desvenlafaxine: Experience with the Effort-Expenditure for Rewards Task (EEfRT) in the VIVRE study.

Gill Hartej, McIntyre Roger S, Christensen Michael Cronquist · J Affect Disord · 2025

PMID: 40456468RCT

A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.

Zhao Qian, Fu Bingbing, Lyu Nan et al. · J Affect Disord · 2023

PMID: 36813043RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Desvenlafaxine (substance)
SNOMED CT: 430267008
UMLS CUI: C1880288
RxNorm CUI: 734064
Labeler: Sun Pharmaceutical Industries, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.